Skip to main
LBRX

LBRX Stock Forecast & Price Target

LBRX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LB Pharmaceuticals is positioned for success with its promising lead drug LB-102, which has a unique pharmacologic profile and favorable clinical data, addressing the significant unmet need for better tolerability and improved efficacy in treating neuropsychiatric disorders. With a strong IP portfolio and potential for partnerships, LB Pharmaceuticals has the potential for significant long-term growth and opportunities in the expanding LAI market. However, investors should be aware of the inherent risks in biotechnology and the potential for setbacks in clinical trials.

Bears say

LB Pharmaceuticals is a late-stage biopharmaceutical company with a focus on developing therapies for neuropsychiatric disorders, including schizophrenia and bipolar depression. The company's promising lead product candidate, LB-102, has shown strong efficacy in clinical trials and has a potentially favorable safety profile. However, the company faces significant competition in the neuropsychiatric market, and its success is dependent on obtaining regulatory approval and effectively defending its intellectual property. The company currently has a negative outlook due to the challenging reimbursement landscape and ongoing market pressures.

LBRX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LB Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LB Pharmaceuticals Inc (LBRX) Forecast

Analysts have given LBRX a Strong Buy based on their latest research and market trends.

According to 5 analysts, LBRX has a Strong Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LB Pharmaceuticals Inc (LBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.